Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
Moderna secured FDA approval for mFLUSIVA, the first mRNA-based seasonal influenza vaccine, for use in adults 50 years of age and older. The approval for adults 50-64 was based on a Phase 3 trial of 40,805 participants, while the indication for those 65 and older received accelerated approval based on immunogenicity data.
Key figures
- Drug Name
- mFLUSIVA (mRNA-1010)
- Phase Of Trial
- Phase 3
- Phase 3 enrollment
- 40805
- Accelerated approval enrollment
- 2992
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.